[go: up one dir, main page]

WO2001022951A3 - Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis - Google Patents

Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis Download PDF

Info

Publication number
WO2001022951A3
WO2001022951A3 PCT/EP2000/008890 EP0008890W WO0122951A3 WO 2001022951 A3 WO2001022951 A3 WO 2001022951A3 EP 0008890 W EP0008890 W EP 0008890W WO 0122951 A3 WO0122951 A3 WO 0122951A3
Authority
WO
WIPO (PCT)
Prior art keywords
biarylbutyric
substituted
treatment
multiple sclerosis
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/008890
Other languages
French (fr)
Other versions
WO2001022951A2 (en
Inventor
Thomas Fahrig
Helmut Haning
Bernd Riedl
Gabriele Braeunlich
Rolf Henning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to JP2001526163A priority Critical patent/JP2003510272A/en
Priority to EP00965974A priority patent/EP1217994A2/en
Priority to AU76536/00A priority patent/AU7653600A/en
Priority to CA002385490A priority patent/CA2385490A1/en
Publication of WO2001022951A2 publication Critical patent/WO2001022951A2/en
Publication of WO2001022951A3 publication Critical patent/WO2001022951A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives for the Prevention and Treatment of Multiple Sclerosis, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula (T)xA-B-D-E-CO2H wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group; x is 0, 1, or 2; the group D represents Formulae (a) or (b), the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.
PCT/EP2000/008890 1999-09-24 2000-09-12 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis Ceased WO2001022951A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001526163A JP2003510272A (en) 1999-09-24 2000-09-12 Use of substituted 4-biarylbutyric acid and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
EP00965974A EP1217994A2 (en) 1999-09-24 2000-09-12 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU76536/00A AU7653600A (en) 1999-09-24 2000-09-12 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
CA002385490A CA2385490A1 (en) 1999-09-24 2000-09-12 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9922710.0 1999-09-24
GBGB9922710.0A GB9922710D0 (en) 1999-09-24 1999-09-24 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
WO2001022951A2 WO2001022951A2 (en) 2001-04-05
WO2001022951A3 true WO2001022951A3 (en) 2001-10-11

Family

ID=10861599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008890 Ceased WO2001022951A2 (en) 1999-09-24 2000-09-12 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis

Country Status (6)

Country Link
EP (1) EP1217994A2 (en)
JP (1) JP2003510272A (en)
AU (1) AU7653600A (en)
CA (1) CA2385490A1 (en)
GB (1) GB9922710D0 (en)
WO (1) WO2001022951A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2832633B1 (en) * 2001-11-28 2004-09-24 Lipha PHARMACEUTICAL COMPOSITION COMPRISING A METFORMIN ASSOCIATION AND A 4-OXO-BUTANOIC ACID AND ITS USE FOR TREATING DIABETES
FR2832927A1 (en) * 2001-12-03 2003-06-06 Lipha PHARMACEUTICAL COMPOSITION COMPRISING A 4-OXO-BUTANOIC ACID AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF DIABETES
FR2834214B1 (en) * 2001-12-28 2004-09-24 Lipha PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND 4-OXO-BUTANOIC ACID AND ITS USE FOR TREATING DIABETES
FR2834640B1 (en) * 2002-01-11 2004-09-24 Lipha PHARMACEUTICAL COMPOSITION COMPRISING A GLITAZONE AND A 4-OXOBUTANOIC ACID AND ITS USE FOR TREATING DIABETES
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
CN103086947A (en) * 2011-11-04 2013-05-08 赵庆春 Phthalimide compounds with antiangiogenic activity and purpose thereof
CN113185447B (en) * 2021-05-06 2023-07-21 四川大学 Phthalylcysteine compounds, their preparation methods and uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015096A1 (en) * 1994-11-15 1996-05-23 Bayer Corporation Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors
WO1997043239A1 (en) * 1996-05-15 1997-11-20 Bayer Corporation Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids
WO1999061413A1 (en) * 1998-05-27 1999-12-02 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015096A1 (en) * 1994-11-15 1996-05-23 Bayer Corporation Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors
WO1997043239A1 (en) * 1996-05-15 1997-11-20 Bayer Corporation Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids
WO1999061413A1 (en) * 1998-05-27 1999-12-02 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONG VOON WEE ET AL: "Matrix metalloproteinases and diseases of the CNS.", TRENDS IN NEUROSCIENCES, vol. 21, no. 2, February 1998 (1998-02-01), pages 75 - 80, XP002161136, ISSN: 0166-2236 *

Also Published As

Publication number Publication date
GB9922710D0 (en) 1999-11-24
AU7653600A (en) 2001-04-30
EP1217994A2 (en) 2002-07-03
CA2385490A1 (en) 2001-04-05
WO2001022951A2 (en) 2001-04-05
JP2003510272A (en) 2003-03-18

Similar Documents

Publication Publication Date Title
MY114686A (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
ATE172731T1 (en) PYRAZOLOPYRIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
FI940951A0 (en) Method of Preparation of Parenteral Antibacterial Composition
AU2001293233A1 (en) Aza heterocyclic derivatives and their therapeutic use
MXPA04005350A (en) Dibenzylamine compound and its pharmaceutical use.
AU2420897A (en) Meta-substituted phenylene sulphonamide derivatives
KR927003052A (en) 2-arylthiazole derivatives and pharmaceutical compositions thereof
WO2003013484A3 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
DE69725978D1 (en) CHALCON DERIVATIVES AND MEDICINES THAT CONTAIN THEM
AU673213B2 (en) Quinoline or quinazoline derivatives, their production and use
IL113778A (en) Condensed-indan derivatives pharmaceutical compositions containing the same and methods for the preparation thereof
KR20050042829A (en) Agent for inhibition of cell adhesion
EP1132379A4 (en) THIOL DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE
CA2119662A1 (en) New nitrogen bicyclic derivatives, their preparation process and pharmaceutical compositions comtaining them
EP0949242A4 (en) Aromatic amine derivatives having nos inhibitory effect
WO2001022951A3 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
CA2211128A1 (en) Epoxysuccinamide derivatives or salts thereof, and drugs containing the same
NO955328D0 (en) Pyridazine derivatives
WO2000050017A3 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
EP1211253A4 (en) TRICYCLIC DIHYDROBENZOFURANES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINES
EP0924204A4 (en) 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
PE62299A1 (en) THERAPEUTIC DERIVATIVES OF NAFTALENE
TW371304B (en) Cephem compounds having antibacterial activity, their production and pharmaceutical composition
FI970452A0 (en) Inhibition of leukotriene biosynthesis by urea derivatives
HUP0302901A2 (en) New derivatives of cyano-aryl (or cyanoheteroaryl)carbonylpiperazinyl-pyrimidines, their preparation, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000965974

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2385490

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 526163

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10088885

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000965974

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000965974

Country of ref document: EP